These authors contributed equally to this work.
Introduction
Hepatocellular carcinoma (HCC) is one of the most common malignancies and the third leading cause of cancer mortality worldwide (1, 2) . Despite the progress in the diagnosis and treatment of HCC, its overall prognosis is still poor, with an approximately 12% survival rate at 5 years (3). The main causes accounting for this dismal prognosis are high levels of invasion and metastasis. However, the molecular mechanisms underlying HCC invasion and metastasis are far from fully understood. Thus, it is of importance to explore the mechanism of HCC invasion and metastasis.
Increasing studies have confirmed that epithelial-mesenchymal transition (EMT) is a crucial step during the invasion and metastasis processes, as EMT enables tumor cells to acquire invasive and migratory abilities (4, 5) . In addition, transforming growth factor-β1 (TGF-β1) is considered as a vital inducer of EMT (6, 7) . Recently, several reports showed that TGF-β1/Smad signaling mediated EMT in cancer, including HCC (8, 9) , but its regulatory mechanism has not yet been elucidated.
Golgi protein 73 (GP73, also termed GOLPH2 and GOLM1) is a type II transmembrane protein that resides in the cis-and medial-Golgi cisternae (10, 11) . It has been reported that elevated expression levels of GP73 occur not only in viral infections (12) (13) (14) (15) but also in certain cancer types, including HCC, lung cancer, gastric cancer and prostate cancer (16) (17) (18) (19) (20) (21) . However, most of the pilot studies have focused on the diagnostic value of GP73 in HCC as a potential tumor biomarker (22) (23) (24) , and its functional mechanism remains obscure. Recently, GP73 was found to enhance tumor growth and metastasis in HCC (25, 26) . Nevertheless, little is known about the roles of GP73 in the mechanisms of metastasis, especially those involving signaling pathways.
Our previous study demonstrated that GP73 is correlated with hallmark EMT molecules: 'E-cadherin and Vimentin in HCC by Immunohistochemistry' (27) . In addition, we have proven that knocking down GP73 inhibits EMT and invasion in HCC (28) . However, the linking pathway through which GP73 promotes EMT and invasion remains unknown. In the present study, we report that GP73 enhanced the EMT process and cell invasion via the induction of TGF-β1. Moreover, GP73 promoted HCC EMT and cell invasion partly via the TGF-β1/Smad2/Smad3 signaling pathway. This may be a novel mechanism by which GP73 accelerates invasion and metastasis in HCC.
Materials and methods

Patients and clinical specimens
Formalin-fixed paraffin-embedded tissues were collected from 80 HCC patients from the First Affiliated Hospital of Xinjiang Medical University, China. These patients who did not receive chemotherapy or radiotherapy before their operations were enrolled from January 2007 to December 2010. This study was approved by the ethics committee of our hospital, and all of the patients signed informed consent forms. Two experienced pathologists confirmed the diagnosis of 'HCC' for all specimens.
Cell lines and mice
Human HCC cell lines HepG2，Bel-7404，MHCC97H and SK-Hep-1 and the human normal liver cell line LO2 were purchased from the Cell Bank of the Chinese Academy of Science (Shanghai, China) in January 2016. The authenticity of cell lines in our study had verified by DNA sequencing using the Applied Biosystems AmpF/STR Identifier kit. All cell lines had never been passaged longer than 4 months and last checked in September 2016. Cells were cultured with Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum (FBS, Gibco, Grand Island, NY) at 37°C in a humidified atmosphere with 5% CO 2 and maintained in Roswell Park Memorial Institute-1640 medium (HyClone).
Male BALB/c nude mice (5 weeks of age, 15-18 g) were obtained from the Beijing Vital River Laboratory Animal Technology Co., Ltd (Beijing, China). All of the mouse experiments were conducted in accordance with the National Institutes of Health Guidelines for the Care and Use of Laboratory Animals. The study protocol was also approved by the Committee on the Use of Animals of Xinjiang Medical University, China.
Reagents
An antibody against GP73 was obtained from Abcam (MA). Human recombinant TGF-β1 was purchased from R&D Systems (Minneapolis, MN).
The TGF-β RI kinase inhibitor SB431542 was obtained from Millipore (Billerica, MA). The following antibodies were used in this study: anti-Ecadherin, anti-N-cadherin, anti-Vimentin, antiphosphorylated Smad2 and antiphosphorylated Smad3 (Cell Signaling Technology, Beverly, MA). β-actin was purchased from Bioworld Technology, CA, USA.
Construction of lentivirus and stable cell lines
Human Lenti-GP73-GFP and Lenti-shGP73-GFP were designed and purchased from GenePharma Technologies (Shanghai, China). Lenti-vector control and Lenti-shcon were designed and purchased from Gene Chem Technologies (Shanghai, China). The transfection was performed according to standard procedures. Following lentiviral infection, single-cell clonal isolates were selected in the presence of 5 µg/ml puromycin (Sigma, USA) for 2 to 4 weeks. GP73 transfection efficiency was determined by realtime PCR and immunoblotting.
RNA isolation and quantitative real-time PCR
Total RNA was extracted using RNAiso Plus (TaKaRa, Japan) and transcribed into cDNA using a PrimeScript™ RT Reagent Kit (TaKaRa) according to the manufacturer's protocols. Quantitative real-time PCR (qRT-PCR) analysis was conducted using SYBR Green Master Mix (Takara), and the assays were performed in triplicate.
Western blot analysis
Cells were harvested and washed twice with phosphate-buffered saline (HyClone); the proteins were extracted using RIPA cell lysis buffer（Beyotime, Jiangsu, China), and the proteins were quantified by using an enhanced bicinchoninic acid Protein Assay Kit (Zhongshan Biotech, Beijing, China). Equal amounts of protein from each group were loaded onto 8-10% SDS-polyacrylamide gel electrophoresis (PAGE) gels (Zhongshan Biotech) and then electrotransferred onto nitrocellulose filter membranes (Millipore, MA) at 200 mA for 2 h. After being blocked for 2 h in 5% non-fat milk, the membranes were cut according to the protein molecular weights and incubated with antibodies. The secondary antibodies were added to the incubation. The membranes were detected using an enhanced chemiluminescence detection system (FDbio, China) according to the manufacturer's instructions.
Scratch assay
For the scratch assay (Haoran, Biotech, Shanghai, China), cells were grown to confluence in a 24-well plate, and a wound line was scratched into the cell monolayer with a sterile 200 ml pipette tip. The width of the wound was measured under a microscope at 0 and 48 h after the scratch to assess the migration ability of the cells.
Transwell assay
Cell invasion was investigated using Matrigel-coated 8.0 μm filter invasion chambers (BD Biosciences, San Jose, CA). Cells were seeded in six-well plates (3 × 10 4 cells/well) and incubated for 24 h. Cells on the upper surface of the membrane were removed using cotton tips after the indicated incubation times. The invading cells attached to the lower surface were stained with crystal violet (500 μl of 5 mg/ml crystal violet dissolved in 20% methanol) and incubated for 30 min. The membrane was washed with phosphate-buffered saline, and the cells on the filter were counted using an optical microscope.
Xenograft studies
Mice were randomly divided into four groups (n = 6). Cells (1 × 10 7 cells in 200 μl) were suspended in Roswell Park Memorial Institute 1640 medium and injected into the tail vein of each BALB/c nude mouse. Six weeks after injection, the mice were examined grossly for the presence of metastases in the lungs. We evaluated tumor metastasis by counting the number of metastatic nodules from each lung sample from each mouse.
Immunofluorescence
For the immunofluorescence of cultured cells, cells were fixed in 4% formaldehyde, permeabilized with 0.2% Triton X-100 and blocked with1% BSA in PBS. Cells were incubated with the primary antibody as indicated overnight at 4°C. After thorough washing, the cells were then incubated
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with fluorescein isothiocyanate-conjugated goat antimouse or antirabbit IgG (Santa Cruz Biotechnology). Finally, the cells were washed and mounted with a mounting medium containing DAPI (Vector Laboratories).
Images were captured using a Leica DMRA fluorescence microscope (Rueil-Malmaison).
Immunohistochemistry
Specimens of tumor tissue were fixed in 10% formalin and embedded in paraffin wax. Three-micrometer sections were then cut from the paraffin blocks for immunohistochemical analysis. The sections were stained with anti-GP73 (1:50), anti-TGF-β1 (1:100) and anti-p-Smad2 (1:100) antibodies at 4°C overnight. The secondary antibody and avidin-biotin-peroxidase complex method were used according to the standard protocols provided by the manufacturer (Vector Laboratories, CA). An immunoglobulin-negative control was used to rule out non-specific binding. These procedures were performed by two independent investigators and one pathologist who was blinded to the model/treatment type for the series of specimens.
Statistical analysis
Statistical analysis was carried out with SPSS software, version 16.0 (SPSS, Chicago). The results are expressed as the mean ± standard deviation (SD).
The data among the groups were compared by one-way analysis of variance followed by Bonferroni correction. Each experiment was performed at least three times independently. Values of P < 0.05 were considered statistically significant (*P < 0.05, **P < 0.01).
Results
GP73 expression levels were associated with HCC metastasis and patient survival
First, at the cellular level, to examine whether the expression of GP73 was associated with metastasis in HCC, we determined GP73 mRNA and protein expression in a variety of cells, including MHCC97-H and SK-Hep-1 (high metastatic) cell lines, HepG2 and Bel-7402 (low metastatic) cell lines and one normal human hepatocyte cell line (LO2). The results in Figure 1A and B show that both GP73 mRNA and proteins levels increased gradually as follows: normal liver cells < HCC cells with low metastatic potential < HCC cells with high metastatic potential. Second, at the tissue level, we measured the GP73 expression levels in 80 cases paraffin-embedded HCC tissue samples by immunohistochemistry. We found more positive GP73 staining cases (30/35) in the metastatic group, compared with the nonmetastatic group (29/45) of HCC tissue samples ( Figure 1C-E) . Moreover, the clinicopathological features of those patients are summarized in Supplementary Table S1, available at Carcinogenesis Online; the data revealed that GP73 levels were associated with not only tumor size (P = 0.037) and tumor node metastasis stage (P = 0.042) but also with distant metastasis (P = 0.041) and vascular invasion (P = 0.020). Furthermore, a Kaplan-Meier survival analysis indicated that patients with a high GP73 expression level (+ +, + + +) had shorter survival times than those with low expression levels (−, +; P = 0.011; Figure 1F ). These data suggest that GP73 plays an important role in HCC invasion and metastasis, as well as in patient survival.
GP73 increased the migration and invasion abilities of HCC cells in vivo and in vitro
To determine the role of GP73 in HCC invasion and metastasis, stable GP73 overexpressing and knockdown cell lines HepG2/ GP73 and SK-Hep-1/shGP73 were made by lentivirus transfection ( Figure 2A ).Transwell invasion assays and scratch woundhealing assays were conducted and are shown in Figure 2B -C. GP73 overexpression promoted the invasion and migration of HepG2 cells compared with the control and blank groups. In contrast, the knockdown of GP73 decreased the invasion and migration abilities of SK-Hep-1 cells.
To determine the effect of GP73 in HCC invasion and metastasis in vivo, we established a tail vein xenograft model to assess HCC cell lung metastasis. HepG2/GP73 and control cells as well as SK-Hep-1/shGP73 and control cells were injected into nude mice via the tail veins; six mice per group. The HepG2/ GP73 group had more metastatic foci than its control group ( Figure 2D-E) , whereas the SK-Hep-1/shGP73 group exhibited less metastatic ability than its control group. These results indicate that GP73 promotes HCC cell invasion and metastasis both in vivo and in vitro.
GP73 facilitated EMT in HCC
Since the invasion and metastasis of HCC cells could be altered by the expression level of GP73, and EMT is a key event associated with tumor invasion and metastasis, we thus hypothesized that GP73 participated in the EMT process in HCC. We found that GP73 overexpression in HepG2 cells decreased the epithelial marker E-cadherin and increased the mesenchymal markers N-cadherin and Vimentin at both the protein and mRNA levels ( Figure 3A-B) . In contrast, the downregulation of GP73 in SK-Hep-1 cells increased E-cadherin and decreased N-cadherin and Vimentin expression. Similar results could be observed by Immunofluorescence detection ( Figure 3C ).These results suggest that GP73 facilitates EMT in hepG2 and SK-Hep-1 cells.
GP73 played a vital role in TGF-β1-induced EMT and cell invasion
As TGF-β1was identified as an important inducer of EMT, we thus intended to investigate whether GP73 promoted EMT and invasion in HCC via TGF-β1 mediation. We treated HepG2 and SK-Hep-1 cells with or without 5 ng/ml TGF-β1 for 24 h. Following TGF-β1 stimulation, both HepG2 and SK-Hep-1 cells exhibited a spindle-shaped and fibroblast-like morphology with mesenchymal phenotype changes. Notably, compared with the controls, HepG2 cells had more significant mesenchymal features with GP73 overexpression, whereas SK-Hep-1 cells had less mesenchymal morphological changes with GP73 knockdown ( Figure 4A ). In addition, we examined the expression of the EMT markers E-cadherin and Vimentin. We found that in the presence of TGF-β1, E-cadherin levels were decreased, and Vimentin was increased in both HepG2 and SK-Hep-1 cells ( Figure 4B ). Importantly, HepG2/GP73 group showed an obvious change in mesenchymal transition, while SK-Hep-1/shGP73 group revealed an apparent change in epithelial transition ( Figure 4B ).
In the Transwell assay, with the mediation of TGF-β1, the number of cells invading through the Matrigel was significantly increased in both HepG2 and SK-Hep-1 cells. Interestingly, HepG2/GP73 cells had more invasive abilities, while SK-Hep-1/ shGP73 cells had less invasion abilities ( Figure 4C) . Collectively, the results indicate that GP73 plays a positive key role in regulating TGF-β1-induced EMT and invasion in HCC.
GP73 promoted EMT and invasion partly via TGF-β1/ Smad signaling
Next, we explored the possible mechanism by which GP73 affected EMT in HCC cells. Several reports have shown that the TGF-β1/Smad signaling pathway plays a vital role in EMT; thus, we proposed that GP73 accelerated EMT and cell invasion via TGF-β1/Smad signaling. We treated the cells with and without TGF-β1 as above and measured the phosphorylated-Smad2 and phosphorylated-Smad3 (p-Smad2, p-Smad3) levels. As shown in Figure 5A , TGF-β1 activated p-Smad2/3 signaling. In addition, the overexpression of GP73 enhanced p-Smad2 and p-Smad3 levels in HepG2 cells, whereas the knockdown of GP73 decreased p-Smad2 and p-Smad3 levels in SK-Hep-1. These data suggest that GP73 can affect the TGF-β1/Smad2/3 signaling pathway.
To negatively validate how GP73 affected TGF-β1/Smad2/3 signaling, we used SB431542 (SB), TGF-β receptor inhibitor, to repress p-Smad2 and p-Smad3 expression. As shown in Figure 5B , E-cadherin levels were restored, and Vimentin expressions were impaired by using SB. At the same time, the number of cells invading through the Matrigel was significantly reduced following SB inhibition ( Figure 5C ). These results indicate that EMT participates in the reversion by blocking the Smad2/3 pathway in HCC.
Western blot analysis showed that in the presence of TGF-β1, the level of GP73 increased, and without the stimulation of TGF-β1, GP73 expression decreased. Conversely, when the TGF-β receptor inhibitor (SB431542) was added, it caused an impaired expression of GP73. Without the presence of SB431542, GP73 expression was restored. This implies that GP73 can be affected by TGF-β1 and SB ( Figure 5D ). Likewise, EMT was reversed, and cell invasion was decreased when GP73 was silenced in SK-Hep-1 cells (Figure 5B-C) .In contrast, EMT and cell invasion were both facilitated when GP73 was overexpressed in HepG2 cells. These results reveal that GP73 plays a key role in regulating HCC EMT and cell mobility. Interestingly, in the case of simultaneously blocking the Smad2/3 pathway, upregulating GP73 resulted in an enhancement of EMT and invasion in HepG2 cells, whereas downregulating GP73 caused a significant decrease in EMT and cell invasion in SK-Hep-1. This indicated that apart from TGF-β1/Smad signaling, GP73 may participate in other cellular pathways in regulating EMT, such as AKT signaling (25) (Figure 5E ). Taken together, The number of metastatic lung foci detected in each group and volume of HCC metastasis were determined after 6 weeks. *P < 0.05，**P < 0.01.
we proved that GP73 promotes HCC EMT and invasion partly via modulating TGF-β1/Smad2/Smad3 signaling at the cellular level.
GP73 positively correlated with TGF-β1/Smad2 pathway activity in HCC tissues
At the tissue level, to explore the correlation between GP73 and TGF-β1/Smad2 signaling expression levels in HCC tissues, we measured these indicators in 80 paired paraffin-embedded specimens. Compared with the normal tissues, the cases of GP73, TGF-β1 and p-Smad2-positive staining in tumor tissues were higher than those in the corresponding normal tissues (all P < 0.001; Figure 6A-C) . Moreover, GP73 was positively associated with TGF-β1 and p-Smad2 expression levels in HCC tissues ( Figure 6D ). These data reveal that GP73 is correlated with EMT and TGF-β1/SMAD signaling in HCC tissues.
Discussion
In our study, we found that GP73 was upregulated in metastatic HCC tissues and predicted a poor prognosis. Consistent with current studies, we confirmed that GP73 facilitated HCC EMT and mobility both in vitro and in vivo. However, the possible mechanism of GP73 that regulates EMT and metastasis remains unknown. For the first time, we report that GP73 plays a vital role in EMT and cell invasion induced by TGF-β1. Furthermore, GP73 stimulated HCC EMT and invasion partly via modulating TGF-β1/Smad2/Smad3 signaling. Our results highlight a novel molecular mechanism through which GP73 could serve as a novel molecular target against EMT in HCC metastasis therapy.
GP73 is a type-II Golgi transmembrane glycoprotein that was originally cloned from a library derived from the liver tissue of a patient with adult giant cell hepatitis (10) . Currently, emerging data are accumulating that serum GP73 increases over the course of HBV infection, fibrosis, cirrhosis and HCC (13, 15, 16) and that GP73 is expressed at higher levels in tumors than in the adjacent tissues (27) . Thus, GP73 has been considered as a potential biomarker for the diagnosis of HCC (22) (23) (24) . At present, few functional studies have reported that GP73 is linked to promoting proliferation and metastasis in HCC (25, 26, 29) . However, the role of GP73 and its regulation mechanism in HCC invasion and metastasis have yet to be addressed.
In this study, we confirm that GP73 plays a critical role in HCC metastasis because GP73 was not only associated with metastasis potential in cell lines but also correlated with tumor size, tumor node metastasis stage, distant metastasis and vascular invasion in human HCC tissues. In addition, this can be supported by our experimental data: GP73 facilitated HCC invasion and migration both in vitro and in vivo. In addition, patients with a high GP73 level had worse survival rates than those with a low GP73 level. This is consistent with Jiang K's findings (30) that GP73 is an indicator of poor outcomes in HCC. The above data suggest that GP73 may serve as an oncogene of HCC because it contributes to invasion and metastasis.
The EMT process is the transformation of epithelial cells to mesenchymal cells. It is characterized by the loss of cell-cell junctions, enhanced cell-matrix adhesion and changes in cell morphology. Cells undergoing EMT exhibit the downregulation of epithelial markers, including E-cadherin, and the upregulation of mesenchymal markers, including N-cadherin and Vimentin. Together, these changes result in cell migration and invasion (31) . We observed that the overexpression of GP73 decreased E-cadherin and increased N-cadherin and Vimentin. In contrast, the downregulation of GP73 increased E-cadherin expression and decreased levels of N-cadherin and Vimentin. These findings are supported by Liu Y's results (29) , which revealed that GP73 promotes invasion and metastasis by accelerating the EMT process in HCC.
TGF-β1 is widely accepted as an important inducer of EMT (6) . It can stimulate tumor cells to undergo a phenotype change to result in increased mobility (7) (8) (9) (10) . Accordingly, our results showed that in the mediation of TGF-β1, HCC cells had a spindleshaped and fibroblast-like morphology and exhibited mesenchymal phenotype changes. Moreover, in the presence of TGF-β1, the EMT process was indeed enhanced, as well as cell invasion. Notably, mesenchymal molecular marker Vimentin expression and cell invasion were enhanced when GP73 was overexpressed. Conversely, Vimentin and cell invasion were weakened when GP73 was knocked down. These results imply that GP73 strengthens the TGF-β1-induced EMT effect. In addition, GP73 participated in TGF-β1-induced EMT and invasion in HCC.
In the TGF-β1-driven EMT pathway, TGF-β receptors displayed on the cell surface recognize ligands and trigger signaling through Smad-dependent and Smad-independent pathways (31) . Canonical TGF-β1 signaling (Smad-dependent) is activated by the phosphorylation of Smad2 and Smad3, which associate with Smad4. Smad2/3/4 complexes can translocate to the nucleus to regulate the transcription of target genes. Apart from the Smad-dependent pathway, Smad-independent signaling pathways, including the PI3K/AKT, JAK/STAT3 and MAPK signaling pathways (11) , can also regulate EMT progression. Among them, the TGF-β1/Smad signal has been the most widely investigated, so we aimed to determine whether GP73 accelerated EMT and cell invasion via TGF-β1/Smad signaling. We treated the cells with and without TGF-β1 and observed that TGF-β1 could activate p-Smad2/3 signaling and promoted EMT. In contrast, the EMT process could be reversed as a result of inhibiting the Smad2/3 pathway using SB431542 (SB). This means that TGF-β1/ Smad-dependent signaling regulates HCC EMT. Moreover, the overexpression of GP73 enhanced p-Smad2/3 levels and EMT, whereas knockdown of GP73 weakened p-Smad2/3 expression levels and impaired EMT in cell lines. These results indicate that GP73 promotes HCC EMT and invasion via modulating TGF-β1/ Smad signaling. Further, we found that the upregulation of GP73 led to enhanced EMT, and the downregulation of GP73 resulted in EMT reversion when the Smad2/3 pathway was blocked. These results provide an implication: apart from TGF-β1/Smad signaling, GP73 may participate in other cellular pathways regulating EMT. This is supported by Xinxin Chen's results (25) , which found that mTOR signaling modulated GP73 expression and that mTOR inhibitors reduced GP73 levels. In addition, we know that mTOR is the downstream molecular signal of the PI3K/Akt pathway.
In summary, we demonstrate that GP73 plays a vital role in EMT and cell invasion induced by TGF-β1. In addition, GP73 promotes HCC EMT partly via the modulation of TGF-β1/Smad signaling. Our results highlight a novel molecular mechanism that provides a therapeutic strategy for HCC metastasis treatment.
